Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Why is Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. ?

With a growth in Net Profit of 60.38%, the company declared Outstanding results in Sep 25

OPERATING CASH FLOW(Y) Highest at CNY 392.77 MM
ROCE(HY) Highest at 15.63%
INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost

With ROE of 13.33%, it has a expensive valuation with a 5.95 Price to Book Value

Over the past year, while the stock has generated a return of 25.10%, its profits have risen by 11.2% ; the PEG ratio of the company is 4
At the current price, the company has a high dividend yield of 0.8

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

25.1%

0.25

38.91%

China Shanghai Composite

24.7%

1.91

12.94%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

10.69%

EBIT Growth (5y)

7.24%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.53

Sales to Capital Employed (avg)

0.39

Tax Ratio

16.34%

Dividend Payout Ratio

36.24%

Pledged Shares

Institutional Holding

ROCE (avg)

38.77%

ROE (avg)

15.88%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

5.95

EV to EBIT

38.08

EV to EBITDA

32.96

EV to Capital Employed

11.96

EV to Sales

13.74

PEG Ratio

4.00

Dividend Yield

0.78%

ROCE (Latest)

31.40%

ROE (Latest)

13.33%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

19What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 392.77 MM

ROCE(HY)

Highest at 15.63%

INTEREST COVERAGE RATIO(Q)

The company hardly has any interest cost

RAW MATERIAL COST(Y)

Fallen by -4.5% (YoY

CASH AND EQV(HY)

Highest at CNY 2,705 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 1.59 times

NET SALES(Q)

Highest at CNY 369.12 MM

OPERATING PROFIT(Q)

Highest at CNY 186.77 MM

OPERATING PROFIT MARGIN(Q)

Highest at 50.6 %

PRE-TAX PROFIT(Q)

Highest at CNY 194.7 MM

NET PROFIT(Q)

Highest at CNY 167.6 MM

EPS(Q)

Highest at CNY 0.32

-1What is not working for the Company

DEBT-EQUITY RATIO (HY)

Highest at -50.18 %

Here's what is working for Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Operating Cash Flow

Highest at CNY 392.77 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Sales

Highest at CNY 369.12 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Net Sales

At CNY 369.12 MM has Grown at 22.64%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Operating Profit

Highest at CNY 186.77 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (CNY MM)

Operating Profit Margin

Highest at 50.6 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at CNY 194.7 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

Highest at CNY 167.6 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.32

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Cash and Eqv

Highest at CNY 2,705 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio

Highest at 1.59 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -4.5% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Debt-Equity Ratio

Highest at -50.18 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio